AcouSort AB (publ) (ACOU.ST)
SEK 11.5
(-0.86%)
SEK 11.5
(-0.86%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 10.55 Million SEK | 112.59% |
| 2022 | 4.96 Million SEK | 65.05% |
| 2021 | 3 Million SEK | -38.98% |
| 2020 | 4.92 Million SEK | 165.52% |
| 2019 | 1.85 Million SEK | 72.81% |
| 2018 | 1.07 Million SEK | -56.73% |
| 2017 | 2.48 Million SEK | -8.82% |
| 2016 | 2.72 Million SEK | 72.79% |
| 2015 | 1.57 Million SEK | -19.09% |
| 2014 | 1.94 Million SEK | 133.87% |
| 2013 | 832.54 Thousand SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 961 Thousand SEK | -29.18% |
| 2024 Q1 | 1.35 Million SEK | 14.81% |
| 2023 Q2 | 1.81 Million SEK | -30.1% |
| 2023 Q4 | 1.18 Million SEK | 5.44% |
| 2023 FY | 5.53 Million SEK | 11.51% |
| 2023 Q3 | 1.12 Million SEK | -38.27% |
| 2023 Q1 | 2.59 Million SEK | 27.98% |
| 2022 FY | 4.96 Million SEK | 65.05% |
| 2022 Q4 | 2.03 Million SEK | 522.7% |
| 2022 Q3 | 326 Thousand SEK | -54.41% |
| 2022 Q2 | 715 Thousand SEK | -62.21% |
| 2022 Q1 | 1.89 Million SEK | 253.64% |
| 2021 Q4 | 535 Thousand SEK | 334.96% |
| 2021 Q1 | 1.81 Million SEK | 54.15% |
| 2021 Q2 | 530 Thousand SEK | -70.86% |
| 2021 Q3 | 123 Thousand SEK | -76.79% |
| 2021 FY | 3 Million SEK | -38.98% |
| 2020 Q3 | 204 Thousand SEK | -85.91% |
| 2020 FY | 4.92 Million SEK | 165.52% |
| 2020 Q1 | 2.09 Million SEK | 560.88% |
| 2020 Q2 | 1.44 Million SEK | -30.88% |
| 2020 Q4 | 1.18 Million SEK | 478.43% |
| 2019 Q2 | 114 Thousand SEK | -87.29% |
| 2019 FY | 1.85 Million SEK | 72.81% |
| 2019 Q4 | 317 Thousand SEK | -40.08% |
| 2019 Q3 | 529 Thousand SEK | 364.04% |
| 2019 Q1 | 897 Thousand SEK | 2142.5% |
| 2018 Q1 | 87 Thousand SEK | -87.05% |
| 2018 Q4 | 40 Thousand SEK | -31.03% |
| 2018 FY | 1.07 Million SEK | -56.73% |
| 2018 Q3 | 58 Thousand SEK | -93.43% |
| 2018 Q2 | 883 Thousand SEK | 914.94% |
| 2017 Q3 | 668 Thousand SEK | -8.74% |
| 2017 FY | 2.48 Million SEK | -8.82% |
| 2017 Q1 | 410 Thousand SEK | -58.96% |
| 2017 Q2 | 732 Thousand SEK | 78.54% |
| 2017 Q4 | 672 Thousand SEK | 0.6% |
| 2016 Q3 | 762 Thousand SEK | 10.12% |
| 2016 FY | 2.72 Million SEK | 72.79% |
| 2016 Q1 | 277 Thousand SEK | 3.61% |
| 2016 Q4 | 999 Thousand SEK | 31.1% |
| 2016 Q2 | 692 Thousand SEK | 149.82% |
| 2015 Q4 | 267.34 Thousand SEK | -46.1% |
| 2015 Q3 | 496 Thousand SEK | 0.0% |
| 2015 FY | 1.57 Million SEK | -19.09% |
| 2014 FY | 1.94 Million SEK | 133.87% |
| 2013 FY | 832.54 Thousand SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 81.842% |
| Ziccum AB (publ) | 3.74 Million SEK | -181.585% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 98.287% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 79.101% |
| Mendus AB (publ) | 28.48 Million SEK | 62.962% |
| Genovis AB (publ.) | 158.23 Million SEK | 93.332% |
| Intervacc AB (publ) | 8.01 Million SEK | -31.641% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -141.221% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 93.81% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 75.964% |
| Aptahem AB (publ) | 2.63 Million SEK | -301.08% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -919.42% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -13602.597% |
| Fluicell AB (publ) | 3.33 Million SEK | -216.087% |
| Saniona AB (publ) | 16.84 Million SEK | 37.346% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 35.692% |
| Biovica International AB (publ) | 7.29 Million SEK | -44.733% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -777.057% |
| Xintela AB (publ) | 78 Thousand SEK | -13426.923% |
| Abliva AB (publ) | 137 Thousand SEK | -7601.46% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 81.682% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -423.883% |
| OncoZenge AB (publ) | 3000.00 SEK | -351600.0% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -6707.097% |
| CombiGene AB (publ) | 5.54 Million SEK | -90.31% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.126% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.385% |
| Corline Biomedical AB | 25.03 Million SEK | 57.847% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -85.822% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -1363.384% |
| I-Tech AB | 120.86 Million SEK | 91.27% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 92.132% |
| Cyxone AB (publ) | 5.14 Million SEK | -104.953% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -49.66% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 1.066% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 6.047% |
| Nanologica AB (publ) | 1.44 Million SEK | -631.185% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -19807.547% |
| BioInvent International AB (publ) | 71.46 Million SEK | 85.235% |
| Alzinova AB (publ) | 270 Thousand SEK | -3807.778% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 70.043% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -621.179% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -273.884% |
| Simris Alg AB (publ) | 4.35 Million SEK | -142.329% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -8016.154% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 95.58% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -45773.913% |